Optimi Health Corp.

OPTI

CA68405H1001

Other Specialty Retailers

Market Closed - Canadian Securities Exchange Other stock markets 03:59:22 2024-04-26 pm EDT			5-day change	1st Jan Change
0.34 ^CAD	-2.86%		+28.30%	+38.78%

Apr. 15	Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient	CI
Apr. 09	Optimi Health Corp. Signs Psilocybin Supply Agreement with Matai Medical Research Institute	CI

3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023.

August 25, 2023

3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023. These Common Share will be under lockup for 912 days starting from 25-FEB-2021 to 26-AUG-2023.

Details:
All securities of an issuer owned or controlled by a Principal (as defined in NP 46-201) must be placed in escrow at the time the issuer distributes its securities or convertible securities to the public by prospectus pursuant to an initial public offering.

Latest news about Optimi Health Corp.

Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient	Apr. 15	CI
Optimi Health Corp. Signs Psilocybin Supply Agreement with Matai Medical Research Institute	Apr. 09	CI
Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract	Apr. 02	CI
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University	Mar. 26	MT
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University	Mar. 26	CI
Optimi Health Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 29	CI
492,000 Warrants of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
606,000 Options of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
Optimi Health Notes Lykos Therapeutics and FDA Priority Review of New Drug Application	Feb. 12	MT
Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding	Feb. 07	CI
Optimi Health Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 28	CI
Optimi Health Secures Amendment to Increase Quantities of MDMA, MDA, and 2C-B	Jan. 19	MT
Optimi Health Granted Precursor Licence to Formulate MDMA, Completes Encapsulation Of Two Dosage Formats	Jan. 03	MT
Sunshine Earth Labs Ltd. and Optimi Health Corp. Announce Strategic Supply Agreement	Dec. 07	CI
Optimi Health Says Achieved Genetics Milestone and Completed Psilocybin Extract Validation and Stability Testing	Nov. 28	MT
Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing	Nov. 28	CI
Optimi Health Corp. Announces Executive Changes	Nov. 07	CI
Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial	23-09-14	CI
3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023.	23-08-25	CI
492,000 Warrants of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023.	23-08-25	CI
606,000 Options of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023.	23-08-25	CI
Optimi Health Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-22	CI
Optimi Health Corp. Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent	23-08-01	CI
Optimi Health Corp. Announces Receipt of Purports Termination Notice	23-07-27	CI

Chart Optimi Health Corp.

Duration

Period

More charts

Company Profile

Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable psychedelic formulations for transformational human experiences. Its products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. It is a supplier of drug and nutraceutical products. The Company works with customers, health food distributors, and drug developers, and patients regulated by Health Canada.

Sector

Other Specialty Retailers

Calendar

2024-05-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Health Food Stores

	1st Jan change	Capi.
OPTIMI HEALTH CORP.	+38.78%	22.12M
THE BETTER BEING CO.	-.--%	843M
DXN HOLDINGS BHD.	-0.79%	657M
NATURAL GROCERS BY VITAMIN COTTAGE, INC.	+5.50%	384M
ZINZINO AB	+23.83%	229M
MARX BIOTECH CO., LTD.	0.00%	141M
NANJING SINOLIFE UNITED COMPANY LIMITED	+134.78%	65.28M